Neuronostics
Neuronostics develops digital biomarkers for neurological conditions, specializing in a cloud-based epilepsy decision support tool called BioEP, which enhances EEG diagnostic processes.
Company Overview
Neuronostics is a company that develops novel digital biomarkers aimed at facilitating faster diagnosis and more effective treatment of neurological conditions. The company utilizes mathematical modeling to create these biomarkers. Established as a spin-out from the University of Exeter in 2018, Neuronostics has garnered support from Innovate UK, the National Institute for Health Research (NIHR), and private equity. It won the Medilink UK National Start-Up of the Year Award in 2020.
BioEP: The Cloud-Based Epilepsy Decision Support Tool
Neuronostics' flagship product, BioEP, is a cloud-based decision support tool designed to significantly improve the diagnostic yield of EEGs for epilepsy. BioEP analyzes EEG data for specific features and brain network-based markers that are elevated in individuals with epilepsy. This tool supports diagnosis from the first EEG and can operate on EEGs with no visible epileptiform activity. BioEP also provides insights to guide the optimal care pathway for patients.
Research and Clinical Trials
Neuronostics is focused on trialing its technology in clinical settings to validate its efficacy and utility. The company partners with various medical and academic institutions, including the University of Exeter, Epilepsy Action, King's College, and several NHS trusts such as NHS Birmingham, NHS Bristol and Weston, NHS Cornwall, NHS Devon and Exeter, NHS Southampton, NHS St George's, NHS UCL, NHS Wales, and NHS Wolverhampton, as well as St Vincent’s Hospital.
Awards and Recognitions
Neuronostics has received several accolades for its innovative work in the medical field. The company was awarded the Medilink UK National Start-Up of the Year Award in 2020. Additionally, the Neuronostics platform has earned the UKCA mark, and the company has been awarded the Epilepsy Positive Mark of Quality by Epilepsy Action.
Investor and Supporter Information
Neuronostics has received substantial support for its initiatives. The company has backing from Innovate UK, the National Institute for Health Research (NIHR), and private equity investors. These supporters provide the necessary funding and resources to help Neuronostics advance its research and technology development in neurological healthcare.